Altimmune, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ALT, updated each market day.
ALT AI Sentiment
AI sees no strong directional signal for Altimmune, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Altimmune, Inc. Common Stock
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Sector
Exchange
Market Cap
$376,003,961
Cap Tier
Employees
57
Headquarters
GAITHERSBURG, MD
Listed Since
Oct. 6, 2005
Website
ALT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALT Volatility
Altimmune, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
